The evidence for pharmacologic treatment of neuropathic cancer pain: Beneficial and adverse effects

Journal of Pain and Symptom Management

Volumn 46, Issue 4, 2013, Pages

  Jongen, Joost L M ^a   Huijsman, Mark L ^a   Jessurun, Jairo ^a   Ogenio, Kennedy ^a   Schipper, David ^a   Verkouteren, Daan R C ^a   Moorman, Peter W ^a   Van Der Rijt, Carin C D ^a   Vissers, Kris C ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

adjuvant analgesic; anticonvulsant; Antidepressant; cancer; neuropathic pain; opioids

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CLONAZEPAM; CODEINE; ETIRACETAM; FLECAINIDE; GABAPENTIN; IMIPRAMINE; KETAMINE; LAMOTRIGINE; MEMANTINE; MORPHINE; NAPROXEN; OPIATE; OXYCODONE; PARACETAMOL; PHENYTOIN; PREGABALIN; TRAMADOL; TRAZODONE; VALPROIC ACID; VENLAFAXINE;

ADVERSE DRUG REACTION; ANALGESIA; CANCER PAIN; DRUG EFFICACY; EFFECT SIZE; EMBASE; HUMAN; MEDLINE; NEUROPATHIC PAIN; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ADJUVANT ANALGESIC; ANTICONVULSANT; ANTIDEPRESSANT; CANCER; NEUROPATHIC PAIN; OPIOIDS;

ANALGESICS, OPIOID; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; NEURALGIA; PREVALENCE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84885297003     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2012.10.230     Document Type: Review

References (47)

1. A. Caraceni, and R.K. Portenoy An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain Pain 82 1999 263 274
2. M.I. Bennett, C. Rayment, and M. Hjermstad Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review Pain 153 2012 359 365
3. C.J. Vecht Nociceptive nerve pain and neuropathic pain Pain 39 1989 243 244
4. S. Grond, L. Radbruch, and T. Meuser Assessment and treatment of neuropathic cancer pain following WHO guidelines Pain 79 1999 15 20
5. N.B. Finnerup, S.H. Sindrup, and T.S. Jensen The evidence for pharmacological treatment of neuropathic pain Pain 150 2010 573 581
6. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Ann Intern Med 151 2009 W65 W94
7. M.I. Bennett Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review Palliat Med 25 2011 553 559
8. V. Bril, J. England, and G.M. Franklin Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation Neurology 76 2011 1758 1765
9. D. Atkins, D. Best, and P.A. Briss Grading quality of evidence and strength of recommendations BMJ 328 2004 1490
10. J.T. Farrar, J.P. Young Jr., L. LaMoreaux, J.L. Werth, and R.M. Poole Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale Pain 94 2001 149 158
11. R.J. Cook, and D.L. Sackett The number needed to treat: a clinically useful measure of treatment effect BMJ 310 1995 452 454
12. R.G. Newcombe Two-sided confidence intervals for the single proportion: comparison of seven methods Stat Med 17 1998 857 872
13. J.R. Hardy, E.A. Rees, and B. Gwilliam A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain J Pain Symptom Manage 21 2001 204 209
14. T.R. Kannan, A. Saxena, S. Bhatnagar, and A. Barry Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients J Pain Symptom Manage 23 2002 60 65
15. H. Hugel, J.E. Ellershaw, and A. Dickman Clonazepam as an adjuvant analgesic in patients with cancer-related neuropathic pain J Pain Symptom Manage 26 2003 1073 1074
16. J.R. Ross, K. Goller, and J. Hardy Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study J Palliat Med 8 2005 1118 1126
17. E.C. Ong Controlled-release oxycodone in the treatment of neuropathic pain of nonmalignant and malignant causes Oncology 74 Suppl 1 2008 72 75
18. N. Tsavaris, P. Kopterides, and C. Kosmas Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study Pain Med 9 2008 1209 1216
19. V. Ventafridda, A. Caraceni, and L. Saita Trazodone for deafferentation pain. Comparison with amitriptyline Psychopharmacology 9 Suppl 1988 S44 S49
20. E. Kalso, T. Tasmuth, and P.J. Neuvonen Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer Pain 64 1996 293 302
21. T. Tasmuth, B. Hartel, and E. Kalso Venlafaxine in neuropathic pain following treatment of breast cancer Eur J Pain 6 2002 17 24
22. S. Mercadante, E. Arcuri, W. Tirelli, P. Villari, and A. Casuccio Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study Tumori 88 2002 239 242
23. A.L. Kautio, M. Haanpaa, T. Saarto, and E. Kalso Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms J Pain Symptom Manage 35 2008 31 39
24. O.J. Vilholm, S. Cold, L. Rasmussen, and S.H. Sindrup Effect of levetiracetam on the postmastectomy pain syndrome Eur J Neurol 15 2008 851 857
25. S. Mishra, S. Bhatnagar, G.N. Goyal, S.P. Rana, and S.P. Upadhya A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study Am J Hosp Palliat Care 29 2012 177 182
26. A. Caraceni, E. Zecca, and C. Bonezzi Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group J Clin Oncol 22 2004 2909 2917
27. R.D. Rao, J.C. Michalak, and J.A. Sloan Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial Cancer 110 2007 2110 2118
28. R.D. Rao, P.J. Flynn, and J.A. Sloan Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial Cancer 112 2008 2802 2808
29. K. Keskinbora, A.F. Pekel, and I. Aydinli Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial J Pain Symptom Manage 34 2007 183 189
30. Y.C. Arai, T. Matsubara, and K. Shimo Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine J Anesth 24 2010 407 410
31. X.M. Li, D.Q. Liu, H.Y. Wu, C. Yang, and L. Yang Controlled-release oxycodone alone or combined with gabapentin for management of malignant neuropathic pain Chin J Canc Res 22 2010 80 86
32. A. Caraceni, E. Zecca, C. Martini, and F. De Conno Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain J Pain Symptom Manage 17 1999 441 445
33. H. Takahashi, and N. Shimoyama A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain Int J Clin Oncol 15 2010 46 51
34. M.Q. Baig, R. Hadi, A. Singhal, and S.K.S. Gautam Role of phenytoin in the management of neurogenic cancer pain Sri Lankan J Anaesthesiol 19 2011 2
35. D. Arbaiza, and O. Vidal Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study Clin Drug Investig 27 2007 75 83
36. S. Mishra, S. Bhatnagar, and D. Gupta Management of neuropathic cancer pain following WHO analgesic ladder: a prospective study Am J Hosp Palliat Care 25 2009 5
37. P.L. Dellemijn, H.B. Verbiest, J.J. van Vliet, P.J. Roos, and C.J. Vecht Medical therapy of malignant nerve pain. A randomised double-blind explanatory trial with naproxen versus slow-release morphine Eur J Cancer 30A 1994 1244 1250
38. R. Dunlop, R.J. Davies, J. Hockley, and P. Turner Analgesic effects of oral flecainide Lancet 1 1988 420 421
39. C. Sinnott, P. Edmonds, I. Cropley, and G. Hanks Flecainide in cancer nerve pain Lancet 337 1991 1347
40. C.F. von Gunten, S. Eappen, and J.F. Cleary Flecainide for the treatment of chronic neuropathic pain: a Phase II trial Palliat Med 21 2007 667 672
41. L.A. Grande, B.R. O'Donnell, D.R. Fitzgibbon, and G.W. Terman Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient Anesth Analg 107 2008 1380 1383
42. C. Sinnott Problems recruiting cancer patients to a comparative clinical trial of drug treatments for neuropathic pain in palliative care J Pain Symptom Manage 23 2002 270 272
43. R.A. Moore, D.J. Gavaghan, J.E. Edwards, P. Wiffen, and H.J. McQuay Pooling data for number needed to treat: no problems for apples BMC Med Res Methodol 2 2002 2
44. S. Arner, and B.A. Meyerson Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain Pain 33 1988 11 23
45. N.I. Cherny, H.T. Thaler, and H. Friedlander-Klar Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies Neurology 44 1994 857 861
46. R.D. Treede, T.S. Jensen, and J.N. Campbell Neuropathic pain: redefinition and a grading system for clinical and research purposes Neurology 70 2008 1630 1635
47. C.S. Cleeland, J.T. Farrar, and F.H. Hausheer Assessment of cancer-related neuropathy and neuropathic pain Oncologist 15 Suppl 2 2010 13 18